US congressman resigns over ASX insider trading penny stock scandal

Can you make money in penny stocks?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Headlines are being made in the US today with a Republican Congressman expected to plead guilty to insider trading charges brought by the US securities regulator the SEC.

Making the case unusual is that the micro-cap biotech in question is ASX-listed Innate Immunotherapeutics Limited (ASX: IIL).

Since the scandal it has changed its name to Amplia Therapeutics Limited (ASX: ATX) perhaps in an effort to brush the episode under the carpet. 

According to reports in The Australian newspaper congressman Chris Collins was tipped off over the phone by the Innate Immunotherapeutics CEO that clinical trial results for one of its drugs were negative.

The congressman in possession of the inside information then tipped off his own son who proceeded to sell large amounts of  shares, while tipping off other associates to run for the hills as well. 

When the negative public announcement came the stock tanked 90% lower, with a journalist named Jerry Zremski working as the Washington Bureau chief of The Buffalo News first picking up the story of suspicious activity. 

Mr Zremski even contacted ex-Motley Fool writer and amateur sleuth Sean O'Neill who had also picked up and flagged the suspicious activity as outlined in the excellent article hyperlinked. 

It was lucky for the local regulator ASIC who had the whole affair picked up for it and pursued with gusto by the feared US regulator the SEC. 

For every case of insider trading picked up (in this case Mr Collins' son's greed in selling straight away appears to have given the game away) there are almost certainly dozens or perhaps hundreds of cases that go undetected or unproven.

Out of the around 2,300 companies listed on the local market the majority fall into the small-cap or speculative buckets. 

At this end of the market even if information is not legally 'inside information' different market participants are often acting on different amounts of information. While misinformation or false representations are also a big problem for retail investors to navigate.

Regulation also cannot be relied upon as the principle of 'caveat emptor' persists.

As Julius Caesar once said; "The faultdear Brutus, is not in our stars, but in ourselves.

I would not suggest punting on speculative stocks unless you are a highly-experienced investor well informed on a particular business.  

You can find some of the more popular speccy ASX stocks across all sectors including mining, healthcare, and biotechnology.

Some popular penny stock names with punters looking to get-rich-quick include Paradigm Biopharmaceuticals Ltd (ASX: PAR), Fastbrick Robotics Ltd (ASX: FBR), Avz Minerals Ltd (ASX: AVZ), Benitec Biopharma Ltd (ASX: BLT) and Bionomics Ltd (ASX: BNO). 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week this Monday.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Guess which popular ASX 200 stock Bell Potter just downgraded

Let's see what the broker is saying on this blue chip.

Read more »

Crude oil barrels rocketing.
ETFs

Why did the BetaShares Crude Oil ETF just spike 4%?

This ETF is attracting buyers in today's seller's market.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why BWP, Metcash, Resolute Mining, and SHAPE shares are pushing higher today

These shares are starting the week on a positive note. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Adairs, ANZ, Aurelia Metals, and Pilbara Minerals shares are falling today

These shares are having a tough start to the week in the red. But why?

Read more »

Miner standing in a mine site with his arms crossed.
Broker Notes

Up 41% in 2025, does Macquarie think Lynas Rare Earths shares have peaked?

The company is up nearly 400% in 5 years.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Share Market News

How far could equity markets fall following the US' attack on Iran?

If oil prices rise, it could be bad news for investors.

Read more »